OCRELIZUMAB for Relapsing-remitting multiple sclerosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 15,658 adverse event reports in the FDA FAERS database where OCRELIZUMAB was used for Relapsing-remitting multiple sclerosis.
Most Reported Side Effects for OCRELIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Covid-19 | 11,454 | 20.4% | 322 | 2,256 |
| Fatigue | 5,704 | 10.2% | 20 | 1,174 |
| Urinary tract infection | 3,618 | 6.4% | 52 | 1,503 |
| Headache | 3,036 | 5.4% | 13 | 660 |
| Multiple sclerosis | 2,609 | 4.6% | 28 | 604 |
| Asthenia | 2,509 | 4.5% | 23 | 879 |
| Nasopharyngitis | 2,479 | 4.4% | 7 | 441 |
| Gait disturbance | 2,384 | 4.2% | 18 | 769 |
| Pneumonia | 2,333 | 4.2% | 132 | 1,254 |
| Pain | 2,327 | 4.1% | 11 | 623 |
| Multiple sclerosis relapse | 2,326 | 4.1% | 7 | 576 |
| Fall | 2,209 | 3.9% | 31 | 973 |
| Off label use | 2,198 | 3.9% | 44 | 629 |
| Infusion related reaction | 2,116 | 3.8% | 5 | 287 |
| Drug ineffective | 2,018 | 3.6% | 14 | 306 |
Other Indications for OCRELIZUMAB
Multiple sclerosis (15,501)
Product used for unknown indication (10,715)
Relapsing multiple sclerosis (6,883)
Primary progressive multiple sclerosis (6,156)
Secondary progressive multiple sclerosis (1,273)
Progressive multiple sclerosis (400)
Multiple sclerosis relapse (373)
Progressive relapsing multiple sclerosis (123)
Neuromyelitis optica spectrum disorder (57)
Rheumatoid arthritis (37)
Other Drugs Used for Relapsing-remitting multiple sclerosis
FINGOLIMOD (8,814)
OFATUMUMAB (3,864)
DIMETHYL (3,638)
NATALIZUMAB (2,749)
INTERFERON BETA-1A (2,058)
GLATIRAMER (1,965)
ALEMTUZUMAB (1,604)
TERIFLUNOMIDE (1,320)
RITUXIMAB (956)
TECFIDERA (806)